New insulins and new insulin regimens: A review of their role in improving glycaemic control in patients with diabetes

Postgraduate Medical Journal

Volumn 85, Issue 1003, 2009, Pages 257-267

  Crasto, W ^a   Jarvis, Janet ^a,c   Khunti, K ^b   Davies, M J ^a,b  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SULFONYLUREA;

DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK ASSESSMENT;

AGE FACTORS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 67649103951     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2008.067926     Document Type: Review

References (89)

1. UK Prospective Diabetes Study (UKPDS) Group (UKPDS 33). Intensive bloodglucose control reduced Type2 diabetes mellitus-related end points. Lancet 1998;352:854-865
2. NHS Information Centre. National Diabetes Audit. Key findings about the quality of care for people with diabetes in England, incorporating registrations from Wales. Report for the audit period 2004/05. http://www.ic.nhs.uk/webfiles/ Services/NCASP/Diabetes/National-Diabetes-Audit-Full-Version-13090601.pdf (accessed 17 Feb 2009).
3. NICE. Clinical guideline 66. Type 2 diabetes: the management of type 2 diabetes. www.nice.org.uk/guidance/CG66 (accessed 17 Feb 2009).
4. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-682 (Pubitemid 35283332)
5. Starke AAR, Heinemann L, Hohmann A, et al. The action profiles of human NPH insulin preparations. Diabet Med 1989;6:239-244 (Pubitemid 19088803)
6. Rutledge KS, Chase HP, Klingensmith GJ, et al. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 1997;100:968-972 (Pubitemid 27516482)
7. Danne T, Aman J, Schober E, et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003;26:2359-2384 (Pubitemid 36993326)
8. Vignati L, Anderson JH Jr, Iversen PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulindependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clin Ther 1997;19:1408-1421 (Pubitemid 28133277)
9. Davey P, Grainger D, MacMillan J, et al. Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis. Clin Ther 1997;19:656-674 (Pubitemid 27425301)
10. Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003;26:799-804. (Pubitemid 36929346)
11. Home PD, Lindholm A, Riis A, et al. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17:762-770 (Pubitemid 32000974)
12. Danne T, Becker Heise T, et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005;28:2100-2115 (Pubitemid 41242451)
13. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with noninsulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997;157:1249-1255 (Pubitemid 27251653)
14. Dailey G, Rosenstock J, Moses RG, et al. Insulin glulisine provides improved glycaemic control in patients with type 2 diabetes. Diabetes Care 2004;27:2363-2368 (Pubitemid 39281386)
15. Ross SA, Zinman B, Campos RV, et al. A comparative study of insulin lispro and regular human insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 2001;24:292-298 (Pubitemid 34100457)
16. Zinman B, Tildesley H, Chiasson JL, et al. Insulin lispro in CSII: results of a doubleblind crossover study. Diabetes 1997;46:440-443 (Pubitemid 27090273)
17. Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus [abstract]. Arch Intern Med 2005;165:1337-1344 (Pubitemid 40973416)
18. Brunelle RL, Llewelyn J, Anderson JH, et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998;21:1726-1731 (Pubitemid 28449815)
19. Plank J, Wutte A, Brunner G, et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002;25:2053-2057 (Pubitemid 41071068)
20. Gray M, Boland EA, Tamborlane WV. Use of lispro insulin and quality of life in adolescents on intensive therapy. The Diabetes Educator 1999;25:934-941
21. Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005;37:702-707 (Pubitemid 41810494)
22. Rave K, Klein O, Frick AD, et al. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006;29:1812-1817 (Pubitemid 44156635)
23. Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. Diabetes Res Clin Pract 2007;76:304-312 (Pubitemid 46400127)
24. Hoogma RP, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res 2006;38:429-433 (Pubitemid 44047966)
25. Soon PC, Matthews DR, Rosskamp R, et al. 24-h profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology. Diabetes 1997;46(Suppl 1):161A.
26. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the longacting insulin analog detemir. Diabetes Care 2008;28:1107-1112 (Pubitemid 40616620)
27. Schober E, Schoenle E, Van Dyk J, et al. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care 2001;24:2005-2006
28. Home PD, Rosskamp R, Forjanic-Klapproth J, et al. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005;21:545-553 (Pubitemid 41646014)
29. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-1136 (Pubitemid 30616801)
30. Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004;66:49-56. (Pubitemid 39201371)
31. De Leeuw I, Vague P, Selam JL, et al. I. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005;7:73-82.
32. Pieber TR, Draeger E, Kristensen A, et al. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22:850-857 (Pubitemid 40942581)
33. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-1620 (Pubitemid 38697678)
34. Pieber TR, Treichel H-C, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with Type1 diabetes using intensive insulin therapy. Diabet Med 2007;24:635-642 (Pubitemid 46808860)
35. Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-1288 (Pubitemid 40756686)
36. Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29:554-559 (Pubitemid 44115353)
37. Massi-Benedetti M, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189-196 (Pubitemid 36577862)
38. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64.
39. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treatto-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274 (Pubitemid 44125921)
40. Hermansen K, Fontaine P, Kukolja K, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-629 (Pubitemid 38658363)
41. Mullins P, Sharplin P, Yki-Jarvinen H, et al. Negative binomial meta-regression analysis combined glycosylated haemoglobin and hypoglycaemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007;356:437-440
42. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycaemia risk with insulin glargine. A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-955
43. Heller S, Kim H. Insulin detemir reduces hypoglycemic risk at comparable HbA1c values to NPH insulin in patients with type 1 diabetes. Diabetes 2005;54(Suppl):487P.
44. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64.
45. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;(2):CD005163. (Pubitemid 351805825)
46. Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005;28:186-212. (Pubitemid 40095803)
47. Bangstad HJ, Danne T, Dub LC, et al. Insulin treatment. ISPAD clinical practice consensus guidelines 2006-2007. Pediatr Diabetes 2007;8:88-102.
48. Hoey H, Aanstoot HJ, Chiarelli F, et al. Good metabolic control is associated with better quality of life in 2,101 adolescents with type 1 diabetes. Diabetes Care 2001;24:1923-1928 (Pubitemid 33716502)
49. Dorchy H. Management of children and adolescents with diabetes mellitus: personal experience. J Pediatr Endocrinol Metab 2003;16:131-148
50. Soliman AT, Omar M, Rizk MM, et al. Glycaemic control with modified intensive insulin injections (MII) using insulin pens and premixed insulin in children with type-1 diabetes: a randomized controlled trial. J Trop Pediatr 2006;52:276-281 (Pubitemid 44304892)
51. Hvidoere Study Group on Childhood Diabetes 2005. Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? Diabetes Care 2005;30:2245-2250
52. Pérez Méndez LF, Alvarez-García E, Alvarez-Vázquez P, et al. Long-term improvement of metabolic control without increased risk of hypoglycaemia by intensive insulin regimens in type 1 diabetes patients treated in a regular clinical setting. Exp Clin Endocrinol Diabetes 2007;115:182-186 (Pubitemid 46640287)
53. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological wellbeing with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001;18:619-625 (Pubitemid 32823058)
54. Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003;20:863-866 (Pubitemid 41701510)
55. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type1 diabetes. Diabetes Care 2002;25:593-598
56. Litton J, Rice A, Friedman N, et al. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002;141:490-495 (Pubitemid 35193313)
57. Ahern JA, Boland EA, Doane R, et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes 2002;3:10-15. (Pubitemid 34618799)
58. Fox LA, Buckloh LM, Smith SD, et al. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 2005;28:1277-1281 (Pubitemid 40756685)
59. DiMeglio LA, Pottorff TM, Boyd SR, et al. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr 2004;145:380-384 (Pubitemid 39165688)
60. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:705. (Pubitemid 34259145)
61. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003;26:1079-1087 (Pubitemid 36929252)
62. Weinzimer SA, Swan KL, Sikes JA, et al. Emerging evidence for the use of insulin pump therapy in infants, toddlers and pre-school aged children with type 1 diabetes. Pediatr Diabetes 2006;7(Suppl 4):15-19. (Pubitemid 44122709)
63. Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in Type 1 diabetes. Diabet Med 2007;24:607-617 (Pubitemid 46808863)
64. Cody D. Infant and toddler diabetes. Arch Dis Child 2007;92:716-719
65. Dorchy H. Management of children and adolescents with diabetes mellitus: personal experience. J Pediatr Endocrinol Metab 2003;16:131-148
66. Hoogma RPLM, Hammond PJ, Gomist R, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5 nations trial. Diabet Med 2006;23:141-147
67. Battelino T. Risk and benefits of continuous subcutaneous insulin infusion (CSII) treatment in school children and adolescents. Pediatr Diabetes 2006;4(Suppl 7):20-24 (Pubitemid 44122710)
68. Retnakaran R, DeVries JH, Hanaire-Broutin H, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: modeling predicted benefits in relationship to baseline A1c. Diabetes Care 2005;28:1835-1836
69. Roze S, Valentine WJ, Zakrzewska KE, et al. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabet Med 2005;22:1239-1245 (Pubitemid 41224186)
70. Masson EA, Patmore JE, Brash PD, et al. Pregnancy outcome in Type 1 diabetes mellitus treated with insulin lispro (Humalog). Diabet Med 2003;20:46-50. (Pubitemid 36104202)
71. Price N, Bartlett C, Gillmer MD. Use of insulin glargine during pregnancy: a casecontrol pilot study. Br J Obstet Gynaecol 2007;114:453-457 (Pubitemid 46393280)
72. Simmons D, Thompson CF, Conroy C, et al. Use of insulin pumps in pregnancies complicated by type 2 diabetes and gestational diabetes in a multiethnic community. Diabetes Care 2001;24:2078-2082 (Pubitemid 33716524)
73. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels, International Diabetes Federation, 2005. http://www.idf.org (accessed 17 Feb 2009).
74. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
75. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
76. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730 (Pubitemid 350005153)
77. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086 (Pubitemid 37339502)
78. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451 (Pubitemid 43277866)
79. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-416
80. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265 (Pubitemid 40170923)
81. Malone JK, Kerr LF, Campaigne BN, et al. Combined therapy with insulin lispro Mix 72/25 plus metformin or insulin glargine plus metformin: a 16-week, randomised, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-2044 (Pubitemid 40353613)
82. Bretzel RG, Arnolds S, Medding J, et al. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004;27:1023-1027 (Pubitemid 38579759)
83. Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine vs. thricedaily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO study). Lancet 2008;371:1073-1084
84. Benjamin G, Erol C. Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. Diabetes Obes Metab 1999;1:67-74.
85. Rosenstock J, Ahmann AL, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-25
86. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003;26:2598-2603 (Pubitemid 37052106)
87. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:2816-2818
88. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730 (Pubitemid 350005153)
89. Yki-Järvinen H, Juurinen L, Alvarsson A, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE). A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007;30:1364-1369